Cargando…

Angiopoietin-2 in Adults with Congenital Heart Disease and Heart Failure

BACKGROUND: Chronic heart failure is an important cause for morbidity and mortality in adults with congenital heart disease (ACHD). While NT-proBNP is an established biomarker for heart failure of non-congenital origin, its application in ACHD has limitations. The angiogenic factors Angiopoietin-1 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lukasz, Alexander, Beutel, Gernot, Kümpers, Philipp, Denecke, Agnieszka, Westhoff-Bleck, Mechthild, Schieffer, Bernhard, Bauersachs, Johann, Kielstein, Jan T., Tutarel, Oktay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691231/ https://www.ncbi.nlm.nih.gov/pubmed/23826161 http://dx.doi.org/10.1371/journal.pone.0066861

Ejemplares similares

Asymmetrical Dimethylarginine - More Sensitive than NT-proBNP to Diagnose Heart Failure in Adults with Congenital Heart Disease
por: Tutarel, Oktay, et al.
Publicado: (2012)

Cardiomyopathies and Congenital Heart Disease in Pregnancy
por: Westhoff-Bleck, Mechthild, et al.
Publicado: (2018)

Depression Associated with Reduced Heart Rate Variability Predicts Outcome in Adult Congenital Heart Disease
por: Westhoff-Bleck, Mechthild, et al.
Publicado: (2021)

Therapeutic Plasma Exchange Decreases Levels of Routinely Used Cardiac and Inflammatory Biomarkers
por: Tutarel, Oktay, et al.
Publicado: (2012)

Prevalence of Child Maltreatment in Adults With Congenital Heart Disease and Its Relationship With Psychological Well-Being, Health Behavior, and Current Cardiac Function
por: Proskynitopoulos, Phileas J., et al.
Publicado: (2021)

Factors That Influence Adherence to Medication in Adults With Congenital Heart Disease (ACHD)
por: Halling, Tim, et al.
Publicado: (2021)

Impact of COVID-19 on Medical Supply in Adults With Congenital Heart Disease
por: Akkermann, Steffen, et al.
Publicado: (2022)

Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays
por: Lukasz, Alexander, et al.
Publicado: (2008)

Behavioral pathway to a broken heart: The link between adverse childhood experiences, depression, physical exercise and cardiovascular health
por: Bertele, Sebastian, et al.
Publicado: (2022)

Impact of relationship status on psychological parameters in adults with congenital heart disease
por: Stapel, Britta, et al.
Publicado: (2023)

Acquired Comorbidities in Adults with Congenital Heart Disease: An Analysis of the German National Register for Congenital Heart Defects
por: Maurer, Susanne J., et al.
Publicado: (2021)

The curse of angiopoietin-2 in ARDS: on stranger TI(E)des
por: Kümpers, Philipp, et al.
Publicado: (2018)

Author reply: S‐ICD eligibilities in adults with congenital heart disease
por: Zormpas, Christos, et al.
Publicado: (2021)

Eligibility for subcutaneous implantable cardioverter‐defibrillator in adults with congenital heart disease
por: Zormpas, Christos, et al.
Publicado: (2021)

Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients
por: Kümpers, Philipp, et al.
Publicado: (2008)

Heart failure drug treatment: the fantastic four
por: Bauersachs, Johann
Publicado: (2021)

NT-proBNP Is a Predictor of Mortality in Adults with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
por: Maurer, Susanne J., et al.
Publicado: (2023)

Involvement of Angiopoietin-2 and Tie2 Receptor Phosphorylation in STEC-HUS Mediated by Escherichia coli O104:H4
por: Lukasz, Alexander, et al.
Publicado: (2015)

Pulmonary Arterial Hypertension Associated with Congenital Heart Disease in Adults over the Age of 40 Years
por: Maurer, Susanne J., et al.
Publicado: (2020)

Small animal models of heart failure
por: Riehle, Christian, et al.
Publicado: (2019)

Role of Angiopoietin/Tie2 in Critical Illness: Promising Biomarker, Disease Mediator, and Therapeutic Target?
por: Lukasz, Alexander, et al.
Publicado: (2012)

Association of serum angiopoietin-1, angiopoietin-2 and angiopoietin-2 to angiopoietin-1 ratio with heart failure in patients with acute myocardial infarction
por: CHEN, SHAOMIN, et al.
Publicado: (2013)

Current and future use of neuromodulation in heart failure( )
por: Duncker, David, et al.
Publicado: (2022)

New drugs: big changes in conservative heart failure therapy?
por: Berliner, Dominik, et al.
Publicado: (2019)

Does low angiopoietin-1 predict adverse outcome in sepsis?
por: David, Sascha, et al.
Publicado: (2010)

Breastfeeding in Patients With Heart Failure: Lack of Evidence and Consensus
por: Koenig, Tobias, et al.
Publicado: (2019)

Transition in Patients with Congenital Heart Disease in Germany: Results of a Nationwide Patient Survey
por: Helm, Paul C., et al.
Publicado: (2017)

Anticoagulants for stroke prevention in heart failure with reduced ejection fraction
por: Schäfer, Andreas, et al.
Publicado: (2021)

COVID-19 Infections in Adults with Congenital Heart Disease—A Prospective Single-Center Study in an Outpatient Setting
por: Langes, Nora, et al.
Publicado: (2022)

Immunity and inflammation: the neglected key players in congenital heart disease?
por: Wienecke, Laura M., et al.
Publicado: (2021)

The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies
por: de Boer, Rudolf A, et al.
Publicado: (2023)

Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC)
por: Berliner, Dominik, et al.
Publicado: (2017)

Serum Angiopoietin-Like Protein 2 Concentrations Are Independently Associated with Heart Failure
por: Huang, Chi-Lun, et al.
Publicado: (2015)

Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
por: Benz, Alexander P, et al.
Publicado: (2023)

A National Comparative Investigation of Twins With Congenital Heart Defects for Neurodevelopmental Outcomes and Quality of Life (Same Same, but Different?): Protocol for a Prospective Observational Study
por: Remmele, Julia, et al.
Publicado: (2021)

Drug treatment of heart failure in the elderly
por: Berliner, D., et al.
Publicado: (2018)

Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure
por: Bavendiek, Udo, et al.
Publicado: (2017)

Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis
por: Kümpers, Philipp, et al.
Publicado: (2009)

Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (ACNAP), the ESC Working Group on Adult Congenital Heart Disease (WG ACHD), the Association for European Paediatric and Congenital Cardiology (AEPC), the Pan-African Society of Cardiology (PASCAR), the Asia-Pacific Pediatric Cardiac Society (APPCS), the Inter-American Society of Cardiology (IASC), the Cardiac Society of Australia and New Zealand (CSANZ), the International Society for Adult Congenital Heart Disease (ISACHD), the World Heart Federation (WHF), the European Congenital Heart Disease Organisation (ECHDO), and the Global Alliance for Rheumatic and Congenital Hearts (Global ARCH)
por: Moons, Philip, et al.
Publicado: (2021)

Antiarrhythmic effects of baroreceptor activation therapy in chronic heart failure: a case report
por: Wang, Dong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h75mol1bkjfgrvnq4jagl0v9gl